Stock Track | WUXI BIO Soars 5.10% Intraday on Acquisition Deal and Sector Tailwinds

Stock Track08-10 09:36

WUXI BIO shares surged 5.10% during intraday trading on Monday, extending a rally driven by the company's recent acquisition announcement and upbeat sentiment across the CXO sector.

The gains follow the August 7 disclosure of a definitive agreement to acquire Transcenta Therapeutics' process development and production base in Hangzhou. The facility is expected to enhance WUXI BIO's integrated end-to-end service capabilities, covering drug substance development, production, and drug product manufacturing. CEO Dr. Zhisheng Chen noted the acquisition further strengthens the company's comprehensive service offering.

Broader sector momentum also provided support after peer WuXi AppTec reported robust first-half results, with revenue rising 38.93% year-over-year and adjusted net profit surging 89.39%. Investors remain optimistic ahead of WUXI BIO's board meeting scheduled for August 25 to review interim results. Other CXO stocks also advanced, with WUXI APPTEC up 4.52%, XTALPI up 8.41%, and INSILICO up 7.35%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173198412?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173198412","market":"hk","top_or_hot":-1,"title":"Stock Track | WUXI BIO Soars 5.10% Intraday on Acquisition Deal and Sector Tailwinds","media":"Stock Track","content":"<p>WUXI BIO shares surged 5.10% during intraday trading on Monday, extending a rally driven by the company's recent acquisition announcement and upbeat sentiment across the CXO sector.</p><p>The gains follow the August 7 disclosure of a definitive agreement to acquire Transcenta Therapeutics' process development and production base in Hangzhou. The facility is expected to enhance WUXI BIO's integrated end-to-end service capabilities, covering drug substance development, production, and drug product manufacturing. CEO Dr. Zhisheng Chen noted the acquisition further strengthens the company's comprehensive service offering.</p><p>Broader sector momentum also provided support after peer WuXi AppTec reported robust first-half results, with revenue rising 38.93% year-over-year and adjusted net profit surging 89.39%. Investors remain optimistic ahead of WUXI BIO's board meeting scheduled for August 25 to review interim results. Other CXO stocks also advanced, with WUXI APPTEC up 4.52%, XTALPI up 8.41%, and INSILICO up 7.35%.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | WUXI BIO Soars 5.10% Intraday on Acquisition Deal and Sector Tailwinds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | WUXI BIO Soars 5.10% Intraday on Acquisition Deal and Sector Tailwinds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-10 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>WUXI BIO shares surged 5.10% during intraday trading on Monday, extending a rally driven by the company's recent acquisition announcement and upbeat sentiment across the CXO sector.</p><p>The gains follow the August 7 disclosure of a definitive agreement to acquire Transcenta Therapeutics' process development and production base in Hangzhou. The facility is expected to enhance WUXI BIO's integrated end-to-end service capabilities, covering drug substance development, production, and drug product manufacturing. CEO Dr. Zhisheng Chen noted the acquisition further strengthens the company's comprehensive service offering.</p><p>Broader sector momentum also provided support after peer WuXi AppTec reported robust first-half results, with revenue rising 38.93% year-over-year and adjusted net profit surging 89.39%. Investors remain optimistic ahead of WUXI BIO's board meeting scheduled for August 25 to review interim results. Other CXO stocks also advanced, with WUXI APPTEC up 4.52%, XTALPI up 8.41%, and INSILICO up 7.35%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1173198412","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173198412","pubTimestamp":1786325803,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"WUXI BIO shares surged 5.10% during intraday trading on Monday, extending a rally driven by the company's recent acquisition announcement and upbeat sentiment across the CXO sector.The gains follow...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"股票追踪|药明生物因收购交易和行业顺风盘中飙升5.10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"WUXI BIO shares surged 5.10% during intraday trading on Monday, extending a rally driven by the company's recent acquisition announcement and upbeat sentiment across the CXO sector.The gains follow the August 7 disclosure of a definitive agreement to acquire Transcenta Therapeutics' process development and production base in Hangzhou. The facility is expected to enhance WUXI BIO's integrated end-to-end service capabilities, covering drug substance development, production, and drug product manufacturing. CEO Dr. Zhisheng Chen noted the acquisition further strengthens the company's comprehensive service offering.Broader sector momentum also provided support after peer WuXi AppTec reported robust first-half results, with revenue rising 38.93% year-over-year and adjusted net profit surging 89.39%. Investors remain optimistic ahead of WUXI BIO's board meeting scheduled for August 25 to review interim results. Other CXO stocks also advanced, with WUXI APPTEC up 4.52%, XTALPI up 8.41%, and INSILICO up 7.35%.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173198412","isCrawlerRequest":true}